NeoGenomics Launches PanTracer LBx, a Liquid Biopsy Comprehensive Genomic Profiling Test (ir.neogenomics.com)

• PanTracer LBx launched July 30, 2025
• Blood-based ctDNA test for comprehensive genomic profiling
• Analyzes >500 genes including MSI and bTMB
• 7-day turnaround time
• Targets patients with advanced solid tumors lacking sufficient tissue

"NeoGenomics announced the launch of PanTracer LBx on July 30, 2025, a blood-based comprehensive genomic profiling (CGP) test using circulating tumor DNA (ctDNA). The test analyzes over 500 genes, including MSI and bTMB, with a seven-day turnaround time. It is intended for patients with advanced solid tumors when tissue samples are insufficient or unavailable. Applications include therapy selection, trial matching, and longitudinal monitoring. The test complements the existing PanTracer portfolio and targets the $3–5 billion liquid biopsy market. NeoGenomics is headquartered in Fort Myers, Florida, and operates CAP/CLIA labs in the US and UK."